aod9604 clinical trials safety efficacy AOD-9604 (10mg vials) AOD 9604 and retatrutide: evidence,

This material is not a drug, medical device, or dietary supplement, and has not been evaluated by the U.S

Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs)

Subcutaneous administration in normal and metabolically dysregulated mice significantly inhibits NNMT activity in metabolically active tissues (adipose, liver, muscle), increases systemic NAD+ levels, enhances mitochondrial function, and improves energy metabolism

Clinical studies and wellness use suggest AOD-9604 has a strong safety profile, especially when compared to HGH or stimulant-based fat burners